METHODS FOR ENGINEERING T-CELL RECEPTORS

• US 20130040836A1
• Filed: 05/29/2012
• Published: 02/14/2013
• Est. Priority Date: 07/05/2006
• Status: Abandoned Application

• Current Assignee: F-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H
• Original Assignee: F-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H
• Inventors: Himmler, Gottfried, Ruker, Florian
• Application Number:
  US13/482,926
• Publication Number:
  US 20130040836A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex

Abstract

The present invention provides a method for engineering a T-cell receptor domain polypeptide comprising at least one modification in a structural loop region of the T-cell receptor domain polypeptide and determining the binding of the T-cell receptor domain polypeptide to an epitope of an antigen, wherein the unmodified T-cell receptor domain polypeptide does not significantly bind to said epitope. The present invention also covers modified T cell receptor domain polypeptides, their use and libraries containing the modified T cell receptor domain polypeptides.

Claims

1. A method for engineering a T-cell receptor domain polypeptide comprising at least one modification in a structural loop region of said T-cell receptor domain polypeptide and determining the binding of said T-cell receptor domain polypeptide to an epitope of an antigen, wherein the unmodified T-cell receptor domain polypeptide does not significantly bind to said epitope, comprising the steps of:

(a) providing a nucleic acid encoding a T-cell receptor domain polypeptide comprising at least one structural loop region,

(b) modifying at least one nucleotide residue of at least one of said structural loop regions,

(c) transferring said modified nucleic acid in an expression system,

(d) expressing said modified T-cell receptor domain polypeptide,

(e) contacting the expressed modified T-cell receptor domain polypeptide with said epitope and

(f) determining whether said modified T-cell receptor domain polypeptide binds to said epitope.

2. The method according to claim 1, wherein said T-cell receptor domain polypeptide is binding specifically to at least two epitopes.

3. The method according to claim 1, characterized in that the T-cell receptor domain polypeptide is of human or murine origin.

4. The method according to claim 1, characterized in that the T-cell receptor domain polypeptide is derived from a T-cell receptor domain selected from the variable or constant domain, preferably from the group consisting of V-alpha, V-beta, V-gamma, V-delta, C-alpha, C-beta, C-gamma, and C-delta.

5. The method according to claim 4, characterized in that the modified structural loop region is derived from a variable domain and comprises at least one modification within amino acids 11 to 19, amino acids 43 to 51, amino acids 67 to 80, or amino acids 90 to 99, where the numbering of the amino acid positions of the domains is that of the IMGT.

6. The method according to claim 4, characterized in that the modified structural loop region is derived from a constant domain and comprises at least one modification within amino acids 9 to 20, amino acids 27 to 36, amino acids 41 to 78, amino acids 82 to 85, amino acids 90 to 102, or amino acids 107 to 116, where the numbering of the amino acid position of the domains is that of the IMGT.

7. The method according to claim 1, characterized in that the modification of at least one nucleotide of a nucleic acid encoding the T-cell receptor domain polypeptide results in a substitution, deletion and/or insertion of one or more amino acids of the T-cell receptor domain polypeptide encoded by said nucleic acid.

8. The method according to claim 1, characterized in that at least one amino acid of at least one structural loop region is modified by site-directed random mutation of at least one nucleic acid molecule.

9. The method according to claim 8, characterized in that the randomly modified nucleic acid molecule comprises at least one nucleotide repeating unit having the coding sequence NNS, NNN, NNK, TMT, WMT, RMC, RMG, MRT, SRC, KMT, RST, YMT, MKC, RSA, or RRC, where the coding is according to IUPAC.

10. A library comprising at least 10 T-cell receptor domain polypeptides obtainable by the method according to claim 1 with a modification in at least one structural loop region.

11. A library comprising at least 10 T-cell receptor domain polypeptides obtainable by the method according to claim 1 with mutations of at least 3 amino acid positions in at least one structural loop region.

12. The library according to claim 10, comprising T-cell receptor domain polypeptides selected from the group consisting of V-alpha, V-beta, V-gamma, V-delta, C-alpha, C-beta, C-gamma, and C-delta.

13. A library comprising at least 10 T-cell receptors obtainable by the method according to claim 1 with at least one modification in at least one structural loop region.

14. A library comprising at least 10 T-cell receptors obtainable by the method according to claim 1 with modifications in at least one structural loop region of a domain selected from the group consisting of V-alpha, V-beta, V-gamma, V-delta, C-alpha, C-beta, C-gamma, and C-delta.

15. A library comprising at least 10 T-cell receptors obtainable by the method according to claim 1 with at least 3 modifications in at least one structural loop region.

16. A method for specifically binding and/or detecting a molecule comprising the steps of:

(a) contacting a library of T-cell receptors according to claim 13, or a modified T-cell receptor domain polypeptide obtainable by a method according to claim 1 with a test sample containing said molecule, and optionally

(b) detecting the potential formation of a specific T-cell receptor/molecule complex.

17. A method for specifically isolating a modified T-cell receptor binding to a molecule comprising the steps of:

(a) contacting a library of T-cell receptors according to claim 13, or a modified T-cell receptor obtainable by a method according to claim 1 with a sample containing said molecule,

(b) separating the specific modified T-cell receptor/molecule complex formed, and

(c) optionally isolating the modified T-cell receptor from said complex.

18. A kit of binding partners containing:

(a) a library of T-cell receptors according to claim 13, or a modified T-cell receptor domain polypeptide obtained by a method according to claim 1, and

(b) a binding molecule containing an epitope of an antigen.

27. A T-cell receptor domain polypeptide obtainable by a method according to claim 1.

19. A T-cell receptor domain polypeptide comprising at least one structural loop region, said at least one loop region comprising at least one modification enabling binding of said at least one modified loop region to an epitope of an antigen wherein the unmodified T-cell receptor domain polypeptide does not bind to said epitope.

20. The T-cell receptor domain polypeptide according to claim 19, that binds to an epitope of an antigen selected from the group consisting of serum proteins, Fc-receptors, complement molecules and serum albumins.

21. A modified T-cell receptor domain polypeptide according to claim 19, with at least two modified structural loop regions.

22. A T-cell receptor comprising at least one modified T-cell receptor domain polypeptide according to claim 19, wherein said modified domain polypeptide portion is selected from the group consisting of V-alpha, V-beta, V-gamma, V-delta, C-alpha, C-beta, C-gamma, and C-delta or a part thereof and said at least one modified structural loop region comprises at least 3 amino acid modifications.

23. A molecule comprising at least one modified T-cell receptor domain polypeptide according to claim 19 and at least one other binding molecule, wherein said other binding molecule is selected from the group of modified T-cell receptor domains according to claim 19, immunoglobulins, soluble receptors, ligands, nucleic acids, and carbohydrates.

24. The molecule according to claim 23, characterised in that the modified loop regions of a V-alpha, V-beta, V-gamma, or V-delta comprise at least one modification within amino acids 11 to 19, amino acids 43 to 51, amino acids 67 to 80, or amino acids 90 to 99, where the numbering of the amino acid position of the domains is that of the IMGT.

25. The molecule according to claim 23, characterised in that the loop regions of a C-alpha, C-beta, C-gamma, or C-delta comprise at least one modification within amino acids 9 to 20, amino acids 27 to 36, amino acids 41 to 78, amino acids 82 to 85, amino acids 90 to 102, or amino acids 107 to 116, where the numbering of the amino acid position of the domains is that of the IMGT.

26. A nucleic acid encoding a T-cell receptor according to claim 26, or part thereof.